GLP 1 Agonists is a recurring topic in our peptide coverage. This hub collects every article tagged GLP 1 Agonists, newest first, each evidence-graded and tied to real, verifiable sources.
The complete alphabetical directory of every peptide in the PeptideVox library — each with its class, highest-confidence evidence grade, and a plain-language summary that keeps human trial data strictly separate from animal, in-vitro and anecdote.
The honest, evidence-first ranking of peptides for weight loss — the GLP-1-based incretin agonists that work in human RCTs, and the 'fat-burning' GH-fragment peptides that failed in human trials.
An evidence-graded review of the peptide drugs studied for metabolic syndrome — from the Grade A incretin drugs that reverse the whole cluster to the preclinical-only compounds sold online with no completed human trial.
An evidence-first ranking of the peptide drugs studied for fatty liver disease (NAFLD/MASLD) and steatohepatitis (MASH) — anchored in biopsy-confirmed human RCTs, not marketing.
A clinical monograph on tirzepatide — the dual GIP/GLP-1 co-agonist sold as Mounjaro and Zepbound. Grade-A RCT evidence for diabetes, obesity and sleep apnea, with a boxed warning and a tightening 2026 compounding landscape.
A clinical monograph on survodutide (BI 456906) — the investigational once-weekly GLP-1/glucagon dual agonist. Grade A randomized evidence in obesity and MASH, but not approved anywhere as of mid-2026.
A clinical monograph on mazdutide (IBI362 / LY3305677) — the first GLP-1/glucagon dual receptor agonist, backed by completed Phase 3 RCTs for obesity and type 2 diabetes, approved in China but investigational in the US.
A clinical monograph on CagriSema — Novo Nordisk's investigational once-weekly cagrilintide + semaglutide combination. Grade A Phase 3 RCT data, ~20-23% weight loss, and a 2026 legal status that is still investigational worldwide.
GLP 1 Agonists is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged GLP 1 Agonists, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.